Administrative Core
行政核心
基本信息
- 批准号:10488238
- 负责人:
- 金额:$ 12.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-13 至 2026-08-31
- 项目状态:未结题
- 来源:
- 关键词:AccountingAddressAdult GlioblastomaBioinformaticsBiologicalBiological MarkersBudgetsClinical TrialsCollaborationsCommunicationConflict (Psychology)DataData ProvenanceDeoxyguanosineDrug TargetingEnsureEvaluationExpenditureFosteringFundingFutureGlioblastomaGoalsGuidelinesInfrastructureInstitutionManuscriptsMediatingMonitorOccupational activity of managing financesOffice of Administrative ManagementPatientsPilot ProjectsPoliciesPreparationProcessProductivityProgram EvaluationPublicationsRegulationReportingResearchResearch PersonnelResearch SubjectsResource SharingResourcesScheduleScienceSiteSpecimenStructureTelomeraseTherapeuticTimeUnited States National Institutes of HealthUniversitiesVisitbiobankconflict resolutiondata integritydata managementearly phase clinical trialimmunogenicinnovationmeetingsnovelnovel strategiesoperationpatient populationpreclinical developmentprofessorquality assurancetelomere
项目摘要
PROJECT SUMMARY – Administrative Core
This Duke/UT Southwestern Glioblastoma Therapeutics Network (GTN) team will complete pre-clinical
development of a novel treatment for patients with glioblastoma (GBM) and investigate the biologic activity of
this agent in an early-phase clinical trial. In support of this goal, this Administrative Core is responsible for
overseeing, integrating, coordinating, and supporting Projects 1 and 2 and the shared Biomarker, Bioinformatics
and Biorepository Core. The Administrative Core will oversee the organizational infrastructure, integration of all
components, and carry out day-to-day administrative activities; serve as the liaison with all internal and external
constituencies; provide support for preparation of reports, manuscripts, and regulatory documents; and foster
team science by facilitating collaboration and smooth communication through regular meetings, seminars, and
other interactions. It will also provide fiscal management to ensure timely financial accounting and reporting
according to university and NIH policies; provide regulatory support to ensure compliance with institutional, state,
and federal research guidelines; oversee data operations to ensure use of best practices for data provenance
and integrity (e.g., monitoring standards such as SOPs, GCP); provide scientific management by monitoring
research progress/productivity and enable effective use of shared resource cores relative to scientific milestones
and budget milestones; conduct ongoing rigorous Program evaluations, with guidance and direction provided by
a Steering Committee and an Internal Advisory Board; resolve conflict; and delineate specific publication and
data distribution policies. Critically, this Core will also oversee interactions with other funded GTN U19 sites,
communication with Network Coordination Center, and the use of yearly trans-U19 Pilot Project Funds. This
Core is structured to reduce administrative burden, allowing investigators to focus on developing a novel
approach for treating adult GBM using an innovative telomerase-mediated telomere-targeting drug, 6-thio-2′-
deoxyguanosine (6-thio-dG), through high-quality, rigorous, and efficient research.
项目概要-行政核心
这个杜克/UT西南胶质母细胞瘤治疗网络(GTN)团队将完成临床前
为胶质母细胞瘤(GBM)患者开发一种新的治疗方法,并研究
这种药物的早期临床试验为支持这一目标,该行政核心负责
监督、整合、协调和支持项目1和2以及共享的生物标志物、生物信息学
和生物储藏核心行政核心将监督组织基础设施,整合所有
各组成部分,并进行日常行政活动;作为联络所有内部和外部
赞助者;为编写报告、手稿和规范性文件提供支持;并促进
通过定期会议、研讨会和
其他互动。它还将提供财务管理,以确保及时进行财务会计和报告
根据大学和NIH的政策;提供监管支持,以确保遵守机构,州,
和联邦研究指南;监督数据操作,以确保使用数据出处的最佳实践
和完整性(例如,监控标准,如SOP、GCP);通过监控提供科学管理
研究进展/生产力,并能够有效利用与科学里程碑相关的共享资源核心
和预算里程碑;进行持续的严格的计划评估,并提供指导和方向
一个指导委员会和一个内部咨询委员会;解决冲突;界定具体的出版物,
数据分发政策。至关重要的是,该核心还将监督与其他受资助的GTN U19网站的互动,
与网络协调中心的沟通,以及每年跨U19试点项目资金的使用。这
核心的结构是为了减少行政负担,使调查人员能够专注于开发一个新的
使用创新的端粒酶介导的端粒靶向药物6-硫代-2 ′-
脱氧鸟苷(6-硫代-dG),通过高质量,严格和有效的研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David M. Ashley其他文献
Phase II study of carboplatin (CBDCA) in progressive low-grade gliomas.
卡铂 (CBDCA) 在进行性低级别胶质瘤中的 II 期研究。
- DOI:
- 发表时间:
1998 - 期刊:
- 影响因子:4.1
- 作者:
Albert Moghrabi;Henry S Friedman;David M. Ashley;K. Bottom;T. Kerby;Elizabeth A. Stewart;Carol S. Bruggers;James M. Provenzale;Martin A. Champagne;Linda Hershon;M. Watral;Janis Ryan;Karima Rasheed;Shelley Lovell;David N. Korones;Herbert E. Fuchs;Timothy M George;R. McLendon;A. Friedman;Edward G. Buckley;D. Longee - 通讯作者:
D. Longee
Brain immunology and immunotherapy in brain tumours
脑肿瘤中的脑免疫学与免疫疗法
- DOI:
10.1038/s41568-019-0224-7 - 发表时间:
2019-12-05 - 期刊:
- 影响因子:66.800
- 作者:
John H. Sampson;Michael D. Gunn;Peter E. Fecci;David M. Ashley - 通讯作者:
David M. Ashley
The evolution of the histology in pleomorphic xanthoastrocytomas in children: a study of 15 cases
儿童多形性黄色星形细胞瘤15例组织学演变
- DOI:
10.1097/pat.0b013e328340bb98 - 发表时间:
2011 - 期刊:
- 影响因子:4.5
- 作者:
Xiangru Wu;P. Bandopadhayay;J. Ng;David M. Ashley;C. Chow - 通讯作者:
C. Chow
A peptide vaccine targeting the CMV antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma: a phase 1 trial
针对患有复发性高级别胶质瘤和髓母细胞瘤的儿童和青少年的针对巨细胞病毒抗原 pp65 的肽疫苗:一项 1 期试验
- DOI:
10.1038/s43018-025-00998-z - 发表时间:
2025-06-12 - 期刊:
- 影响因子:28.500
- 作者:
Eric M. Thompson;David M. Ashley;Katayoun Ayasoufi;Pamela Norberg;Gerald Archer;Evan D. Buckley;James E. Herndon;Ashley Walter;Bridget Archambault;Charlene Flahiff;Denise Jaggers;Laura Gorski;Luis A. Sanchez;Kendra Congdon;Kelly Hotchkiss;Sarah L. Cook;Eliese Moelker;Gordana Vlahovic;Elizabeth Reap;Kristin Schroeder;Dina Randazzo;Annick Desjardins;Margaret O. Johnson;Katherine Peters;Mustafa Khasraw;Henry Friedman;Duane A. Mitchell;John H. Sampson;Daniel Landi - 通讯作者:
Daniel Landi
The Role of Social Support in Families Coping with Childhood Brain Tumor
社会支持在家庭应对儿童脑肿瘤中的作用
- DOI:
10.1080/07347330802614634 - 发表时间:
2009 - 期刊:
- 影响因子:2.1
- 作者:
A. Jackson;Kate Enderby;M. O'Toole;Shane. Thomas;David M. Ashley;J. Rosenfeld;E. Simos;Nicole Tokatlian;R. Gedye - 通讯作者:
R. Gedye
David M. Ashley的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David M. Ashley', 18)}}的其他基金
ATRX mutations, innate immune activation and therapeutic vulnerability in malignant gliomas
ATRX 突变、先天免疫激活和恶性胶质瘤的治疗脆弱性
- 批准号:
10375084 - 财政年份:2022
- 资助金额:
$ 12.35万 - 项目类别:
ATRX mutations, innate immune activation and therapeutic vulnerability in malignant gliomas
ATRX 突变、先天免疫激活和恶性胶质瘤的治疗脆弱性
- 批准号:
10666347 - 财政年份:2022
- 资助金额:
$ 12.35万 - 项目类别:
6-thio-2'-deoxyguanosine: A Novel Immunogenic Telomerase-Mediated Therapy in Glioblastoma - A Duke and UTSW Collaboration
6-硫代-2-脱氧鸟苷:一种新型免疫原性端粒酶介导的胶质母细胞瘤疗法 - 杜克大学和 UTSW 合作
- 批准号:
10305565 - 财政年份:2021
- 资助金额:
$ 12.35万 - 项目类别:
6-thio-2'-deoxyguanosine in GBM: Pre-clinical Evaluation of Mechanism of action, Efficacy and Biomarker identification
GBM 中的 6-硫代-2-脱氧鸟苷:作用机制、功效和生物标志物鉴定的临床前评估
- 批准号:
10488242 - 财政年份:2021
- 资助金额:
$ 12.35万 - 项目类别:
6-thio-2'-deoxyguanosine: A Novel Immunogenic Telomerase-Mediated Therapy in Glioblastoma - A Duke and UTSW Collaboration
6-硫代-2-脱氧鸟苷:一种新型免疫原性端粒酶介导的胶质母细胞瘤疗法 - 杜克大学和 UTSW 合作
- 批准号:
10488237 - 财政年份:2021
- 资助金额:
$ 12.35万 - 项目类别:
6-thio-2'-deoxyguanosine in GBM: Pre-clinical Evaluation of Mechanism of action, Efficacy and Biomarker identification
GBM 中的 6-硫代-2-脱氧鸟苷:作用机制、功效和生物标志物鉴定的临床前评估
- 批准号:
10305568 - 财政年份:2021
- 资助金额:
$ 12.35万 - 项目类别:
Is Low Tumor Mutational Burden Predictive of Response to Oncolytic Polio Virus Therapy in Recurrent Glioblastoma?
低肿瘤突变负荷是否可以预测复发性胶质母细胞瘤对溶瘤脊髓灰质炎病毒治疗的反应?
- 批准号:
9807277 - 财政年份:2019
- 资助金额:
$ 12.35万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 12.35万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 12.35万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 12.35万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 12.35万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 12.35万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 12.35万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 12.35万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 12.35万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 12.35万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 12.35万 - 项目类别:
Research Grant